January 2019

Adelaide, Australia, 18 January 2019 – GPN Vaccines, a vaccine development company focussed on the prevention of diseases caused by the world’s foremost bacterial pathogen, Streptococcus pneumoniae, has raised AUD$1.1 million (USD$0.8 million) towards development of its proprietary vaccine, Gamma-PN. The investment round included strong support from existing shareholders...

Protecting children and adults from the world’s foremost bacterial pathogen